Treatment of B cell malignancies with 131I LYM‐1 monoclonal antibodies

S. J. Denardo, Gerald L Denardo, L. F. O'Grady, E. Hu, V. M. Sytsma, S. L. Mills, N. B. Levy, D. J. Macey, C. H. Miller, A. L. Epstein

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Lym‐1 is a murine IgG2a monoclonal antibody (MAb) that is B‐cell specific but has greater avidity for malignant B cells when compared with normal B lymphocytes. It was originally produced by immunizing mice with nuclei of cultured cells from a patient with Burkitt's lymphoma. Ten patients with progressive refractory B‐cell malignancies were treated with 131I‐labelled Lym‐1. Treatment with 131I Lym‐1 produced complete or partial remissions in 4 patients. Toxicity did not occur or was mild in most patients. The only significant complications included two instances of fistula secondary to necrotic lymphoma and one instance of hypotension. Human antimouse antibodies occurred in only 2 patients after multiple injections of Lym‐1 antibody. This experience was in contrast to treatment of B‐cell malignancies with unconjugated Lym‐1 alone. Unconjugated Lym‐1 also caused no significant toxicity but was less effective than 131I Lym‐1.

Original languageEnglish (US)
Pages (from-to)96-101
Number of pages6
JournalInternational Journal of Cancer
Volume41
Issue number3 S
DOIs
StatePublished - 1988

Fingerprint

B-Lymphocytes
Monoclonal Antibodies
Neoplasms
Therapeutics
Burkitt Lymphoma
Antibodies
Hypotension
Fistula
Cultured Cells
Lymphoma
Injections

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Denardo, S. J., Denardo, G. L., O'Grady, L. F., Hu, E., Sytsma, V. M., Mills, S. L., ... Epstein, A. L. (1988). Treatment of B cell malignancies with 131I LYM‐1 monoclonal antibodies. International Journal of Cancer, 41(3 S), 96-101. https://doi.org/10.1002/ijc.2910410819

Treatment of B cell malignancies with 131I LYM‐1 monoclonal antibodies. / Denardo, S. J.; Denardo, Gerald L; O'Grady, L. F.; Hu, E.; Sytsma, V. M.; Mills, S. L.; Levy, N. B.; Macey, D. J.; Miller, C. H.; Epstein, A. L.

In: International Journal of Cancer, Vol. 41, No. 3 S, 1988, p. 96-101.

Research output: Contribution to journalArticle

Denardo, SJ, Denardo, GL, O'Grady, LF, Hu, E, Sytsma, VM, Mills, SL, Levy, NB, Macey, DJ, Miller, CH & Epstein, AL 1988, 'Treatment of B cell malignancies with 131I LYM‐1 monoclonal antibodies', International Journal of Cancer, vol. 41, no. 3 S, pp. 96-101. https://doi.org/10.1002/ijc.2910410819
Denardo, S. J. ; Denardo, Gerald L ; O'Grady, L. F. ; Hu, E. ; Sytsma, V. M. ; Mills, S. L. ; Levy, N. B. ; Macey, D. J. ; Miller, C. H. ; Epstein, A. L. / Treatment of B cell malignancies with 131I LYM‐1 monoclonal antibodies. In: International Journal of Cancer. 1988 ; Vol. 41, No. 3 S. pp. 96-101.
@article{82cb53e6ba85478798d19a612d537495,
title = "Treatment of B cell malignancies with 131I LYM‐1 monoclonal antibodies",
abstract = "Lym‐1 is a murine IgG2a monoclonal antibody (MAb) that is B‐cell specific but has greater avidity for malignant B cells when compared with normal B lymphocytes. It was originally produced by immunizing mice with nuclei of cultured cells from a patient with Burkitt's lymphoma. Ten patients with progressive refractory B‐cell malignancies were treated with 131I‐labelled Lym‐1. Treatment with 131I Lym‐1 produced complete or partial remissions in 4 patients. Toxicity did not occur or was mild in most patients. The only significant complications included two instances of fistula secondary to necrotic lymphoma and one instance of hypotension. Human antimouse antibodies occurred in only 2 patients after multiple injections of Lym‐1 antibody. This experience was in contrast to treatment of B‐cell malignancies with unconjugated Lym‐1 alone. Unconjugated Lym‐1 also caused no significant toxicity but was less effective than 131I Lym‐1.",
author = "Denardo, {S. J.} and Denardo, {Gerald L} and O'Grady, {L. F.} and E. Hu and Sytsma, {V. M.} and Mills, {S. L.} and Levy, {N. B.} and Macey, {D. J.} and Miller, {C. H.} and Epstein, {A. L.}",
year = "1988",
doi = "10.1002/ijc.2910410819",
language = "English (US)",
volume = "41",
pages = "96--101",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3 S",

}

TY - JOUR

T1 - Treatment of B cell malignancies with 131I LYM‐1 monoclonal antibodies

AU - Denardo, S. J.

AU - Denardo, Gerald L

AU - O'Grady, L. F.

AU - Hu, E.

AU - Sytsma, V. M.

AU - Mills, S. L.

AU - Levy, N. B.

AU - Macey, D. J.

AU - Miller, C. H.

AU - Epstein, A. L.

PY - 1988

Y1 - 1988

N2 - Lym‐1 is a murine IgG2a monoclonal antibody (MAb) that is B‐cell specific but has greater avidity for malignant B cells when compared with normal B lymphocytes. It was originally produced by immunizing mice with nuclei of cultured cells from a patient with Burkitt's lymphoma. Ten patients with progressive refractory B‐cell malignancies were treated with 131I‐labelled Lym‐1. Treatment with 131I Lym‐1 produced complete or partial remissions in 4 patients. Toxicity did not occur or was mild in most patients. The only significant complications included two instances of fistula secondary to necrotic lymphoma and one instance of hypotension. Human antimouse antibodies occurred in only 2 patients after multiple injections of Lym‐1 antibody. This experience was in contrast to treatment of B‐cell malignancies with unconjugated Lym‐1 alone. Unconjugated Lym‐1 also caused no significant toxicity but was less effective than 131I Lym‐1.

AB - Lym‐1 is a murine IgG2a monoclonal antibody (MAb) that is B‐cell specific but has greater avidity for malignant B cells when compared with normal B lymphocytes. It was originally produced by immunizing mice with nuclei of cultured cells from a patient with Burkitt's lymphoma. Ten patients with progressive refractory B‐cell malignancies were treated with 131I‐labelled Lym‐1. Treatment with 131I Lym‐1 produced complete or partial remissions in 4 patients. Toxicity did not occur or was mild in most patients. The only significant complications included two instances of fistula secondary to necrotic lymphoma and one instance of hypotension. Human antimouse antibodies occurred in only 2 patients after multiple injections of Lym‐1 antibody. This experience was in contrast to treatment of B‐cell malignancies with unconjugated Lym‐1 alone. Unconjugated Lym‐1 also caused no significant toxicity but was less effective than 131I Lym‐1.

UR - http://www.scopus.com/inward/record.url?scp=84987480164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987480164&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910410819

DO - 10.1002/ijc.2910410819

M3 - Article

C2 - 3209308

AN - SCOPUS:84987480164

VL - 41

SP - 96

EP - 101

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3 S

ER -